Antipsychotics (Neuroleptics) for Myofascial Pain

The use of antipsychotic medications at sub-psychiatric doses for chronic pain management is not a recent development — it reflects a pharmacological principle that is often counterintuitive to clinicians: the same receptor profile that produces antipsychotic effects at high doses produces quite different, and clinically useful, effects at low doses. At 12.5 to 25 mg, chlorpromazine and levomepromazine are not functioning primarily as D2 blockers — they are functioning as potent H1 antihistamines, alpha-1 antagonists, and mild anticholinergics. These properties collectively produce sedation, muscle relaxation, and central pain modulation that can be invaluable in refractory myofascial pain syndrome.

The historical role of phenothiazines in pain management predates the modern opioid era. In the 1960s and 1970s, before the widespread availability of tricyclic antidepressants for pain and long before SNRIs and gabapentinoids, phenothiazines such as chlorpromazine and levomepromazine were routinely used in chronic pain clinics and palliative care settings. The analgesic properties of these agents were well-recognized, and some pain management traditions — particularly in palliative care — have maintained this practice more robustly than general internal medicine settings, which largely moved toward newer agents.

The current evidence base for neuroleptics in MPS and related conditions is largely observational, with stronger randomized controlled trial data in specific populations. The best evidence exists for cancer-related pain (where levomepromazine and haloperidol have established roles as opioid adjuvants and antiemetics), and for fibromyalgia (where quetiapine at low doses has shown benefit in several small RCTs — particularly for the sleep and pain components). For MPS specifically, the evidence is extrapolated from these adjacent conditions and from the mechanistic rationale. No large RCT specifically addresses low-dose neuroleptics for trigger point-based myofascial pain, which is a genuine gap in the literature.

Despite the availability of newer agents, low-dose neuroleptics remain relevant in clinical practice for several reasons that go beyond evidence gaps. First, cost and accessibility: in many markets, first-generation agents like chlorpromazine and levomepromazine are extremely low-cost and familiar to both prescribers and patients in chronic pain subspecialties. Second, specific comorbid profiles: no other drug class simultaneously addresses severe insomnia, anxiety-driven pain amplification, nausea from other medications, and central pain sensitization — the combination that neuroleptics address through their multi-receptor profile. Third, when patients have already failed or are intolerant of TCAs, SNRIs, and gabapentinoids, the neuroleptics represent a genuinely different pharmacological approach rather than a variation on the same mechanism.

The strongest evidence for neuroleptics as analgesic adjuvants comes from oncology and palliative care. In cancer pain, levomepromazine and methotrimeprazine have been used as opioid-sparing adjuvants for decades, with case series and small trials supporting their role for refractory cancer pain in combination with opioids. Haloperidol has similar palliative-care experience as an opioid co-analgesic. This evidence base has been extrapolated, with clinical justification rather than direct RCT support, to non-malignant chronic pain — the mechanisms of opioid potentiation and central pain modulation are not inherently cancer-specific.

For fibromyalgia — a condition that substantially overlaps with and often co-exists with widespread MPS — a small number of trials have examined low-dose quetiapine. The Potvin et al. 2012 pilot RCT (Journal of Clinical Psychopharmacology, PMID 22926604) found quetiapine 50–300 mg/day improved sleep but did not significantly improve pain at 12 weeks. Subsequent RCTs (Calandre 2014; McIntyre 2014) compared quetiapine extended-release with amitriptyline or placebo in patients with comorbid depression. The collective signal is for sleep and mood benefit rather than direct analgesia. For the broader MPS population without fibromyalgia, the evidence remains observational, and mechanistic extrapolation rather than direct trial data drives prescribing.